GSK (MEX:GSKN) Cyclically Adjusted Revenue per Share: MXN417.53 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:GSKN GSK PLC MEX:GSKN
73 GF Score
Price MXN922.00
GF Value MXN787.75
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is GSK Cyclically Adjusted Revenue per Share?

GSK MEX:GSKN 73 Cyclically Adjusted Revenue per Share is MXN417.53 as of Jun. 2026. GuruFocus rates MEX:GSKN with a GF Score™ of 73/100 and a GF Value™ of MXN787.75 (Modestly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GSK's adjusted revenue per share for the three months ended in Jun. 2026 was MXN96.326. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN417.53 for the trailing ten years ended in Jun. 2026.

During the past 12 months, GSK's average Cyclically Adjusted Revenue Growth Rate was 1.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 2.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of GSK was 9.10% per year. The lowest was 0.60% per year. And the median was 4.20% per year.

As of today (2026-08-09), GSK's current stock price is MXN922.00. GSK's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN417.53. GSK's Cyclically Adjusted PS Ratio of today is 2.21.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.49. The lowest was 1.48. And the median was 2.01.


GSK  (MEX:GSKN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GSK's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=922.00/417.53
=2.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.49. The lowest was 1.48. And the median was 2.01.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GSK Cyclically Adjusted Revenue per Share Related Terms


GSK Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for GSK's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Cyclically Adjusted Revenue per Share Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 539.29 387.39 363.47 418.53 422.88

GSK Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 503.62 422.99 422.88 450.97 417.53

MEX:GSKN vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted PS Ratio falls into.


MEX:GSKN
73GF Score
GSK PLC MEX:GSKN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GSK's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=96.326/142.3000*142.3000
=96.326

Current CPI (Jun. 2026) = 142.3000.

GSK Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 97.729 101.500 137.013
201612 98.475 102.200 137.113
201703 87.254 102.700 120.898
201706 86.668 103.500 119.158
201709 96.140 104.300 131.167
201712 101.140 105.000 137.069
201803 92.644 105.100 125.435
201806 96.255 105.900 129.340
201809 99.486 106.600 132.804
201812 102.152 107.100 135.726
201903 98.330 107.000 130.770
201906 95.230 107.900 125.591
201909 114.492 108.400 150.297
201912 108.658 108.500 142.507
202003 131.632 108.600 172.479
202006 109.620 108.800 143.372
202009 122.722 109.200 159.921
202012 -13.321 109.400 -17.327
202103 104.381 109.700 135.400
202106 80.728 111.400 103.120
202109 92.342 112.400 116.906
202112 95.064 114.700 117.939
202203 92.778 116.500 113.325
202206 67.587 120.500 79.814
202209 87.254 122.300 101.523
202212 85.651 125.300 97.272
202303 74.445 126.800 83.545
202306 75.923 129.400 83.492
202309 85.425 130.100 93.436
202312 83.985 130.500 91.579
202403 75.503 131.600 81.642
202406 89.161 133.000 95.396
202409 100.785 133.500 107.429
202412 102.966 135.100 108.453
202503 96.041 136.100 100.416
202506 99.285 138.400 102.083
202509 103.304 138.900 105.833
202512 101.803 139.900 103.549
202603 90.048 140.800 91.007
202606 96.326 142.300 96.326

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN417.53 mean?
GSK (MEX:GSKN) has a Cyclically Adjusted Revenue per Share of MXN417.53 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on GSK and its competitors.
Is GSK's Cyclically Adjusted Revenue per Share too high?
GSK's current Cyclically Adjusted Revenue per Share is MXN417.53. Overall, GSK has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
GSK's Cyclically Adjusted Revenue per Share of MXN417.53 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on GSK and its competitors. GSK's current Cyclically Adjusted Revenue per Share is MXN417.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (MEX:GSKN) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN787.75, compared to a current price of MXN922.00 — trading 17% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN417.53. GSK's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For GSK (MEX:GSKN), the current Cyclically Adjusted Revenue per Share is MXN417.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (MEX:GSKN) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of MXN922.00 is trading 17% above its estimated GF Value™ of MXN787.75. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for MEX:GSKN:

  • Cyclically Adjusted Revenue per Share: MXN417.53
  • GF Value™: MXN787.75 vs. price of MXN922.00 (17% above fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the MEX:GSKN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
73GF Score

Get the complete analysis for MEX:GSKN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN922.00
Price
MXN787.75
GF Value